Oligometastases, or oligometastatic disease, refers to a distant disease that is limited in number and distribution, Niibe et al. defined this as ≤5 metastatic/recurrent lesions with control of the primary lesion.

Also, there has been established a maximum of 3 different metastatic sites.

These metastases can be treated with local measures (surgery, radiation therapy, thermal ablation, etc.) with the aim of increasing survival. This is a shift from traditional thinking where the metastatic disease was considered an end-stage disease with limited treatment options.

Oligometastatic disease refers to a state in which a patient with cancer has a limited number of metastatic lesions, typically five or fewer. The goal of treating oligometastases with rSBRT is to eliminate or control these metastases, potentially extending the patient's disease-free interval and overall survival.

Rosenbrock et al. presented a retrospective analysis focused on the effectiveness and safety of robotic stereotactic body radiotherapy (rSBRT) for treating lung cancer metastases in patients with oligometastatic disease.

1. Research Context and Objectives: The abstract provides a clear overview of the research's context by explaining the significance of rSBRT in treating lung metastases among patients with oligometastatic disease. The objective is well-defined: to assess the local control rate, progression-free survival, overall survival, and toxicity associated with rSBRT, while identifying independent factors influencing its efficacy and safety.

2. Patient Cohort and Methodology: The methodology mentions a retrospective single-center analysis of patients with various cancer types who underwent rSBRT using the Accuray Cyberknife® device. This description provides an understanding of the patient demographics and the treatment modality used, which enhances the study's credibility. The temporal scope (2012-2019) and the inclusion of different cancer types emphasize the study's generalizability.

3. Treatment Outcomes: The abstract presents essential treatment outcomes, such as the 4-year Kaplan-Meier estimates for local control rate (LC), progression-free survival (PFS), and overall survival (OS). These metrics provide insights into the effectiveness of rSBRT in managing lung metastases. The reported LC of 72.0% suggests favorable tumor control, while the lower PFS (12.4%) and OS (49.7%) indicate challenges in preventing disease progression and achieving long-term survival, which is common in metastatic settings.

4. Factors Influencing Treatment Efficacy: The study conducts a Cox regression analysis to identify independent factors affecting the efficacy of rSBRT. Notably, it finds that LC for metastases from colorectal carcinoma and those treated with a lower biological effective dose (BED10) is significantly worse. This finding underscores the importance of tailoring treatment parameters based on tumor histology and radiation dose to optimize outcomes.

5. Safety and Toxicity: The abstract mentions the occurrence of grade I-II pneumonitis in 21.4% of cases treated with rSBRT. This information highlights the potential toxicity associated with the treatment, which is crucial for evaluating the overall risk-benefit profile of rSBRT.

6. Conclusion: The study concludes that rSBRT is an effective and safe therapy for lung metastases, aligning with the initial hypothesis. It also suggests that aiming for a higher BED10 (>100 Gy) is advisable, particularly for radioresistant histologies such as colorectal carcinoma, to improve treatment outcomes.

7. Limitations and Future Directions: While the abstract provides valuable insights, it's important to acknowledge potential limitations. Being a retrospective study from a single center, there might be inherent biases and generalizability concerns. Additionally, the abstract doesn't elaborate on the specific clinical and treatment-related characteristics of patients, which could provide a deeper understanding of the results.

In conclusion, this abstract contributes valuable information to the field of rSBRT for lung metastases in patients with oligometastatic disease. The study's findings, particularly regarding factors influencing efficacy and the importance of radiation dose, can guide future research and clinical decision-making [1].

[1]

Rosenbrock J, Lieser A, Ostermann-Myrau J, Judge M, Linde P, Claus K, Marnitz S, Kocher M, Baues C, Celik E. Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease. Anticancer Res. 2023 Sep;43(9):4125-4131. doi: 10.21873/anticanres.16602. PMID: 37648304.

From:
https://neurosurgerywiki.com/wiki/ - **Neurosurgery Wiki**

Permanent link:
https://neurosurgerywiki.com/wiki/doku.php?id=oligometastatic_disease

Last update: **2024/06/07 02:59**